Clinical Trial

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
The main objective of the study is to evaluate the efficacy and safety of maintenance therapy with hypomethylating agent and Venetoclax to improve leukemia free survival for high-risk myeloid malignancies after allogeneic hematopoietic stem cell transplantation .
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-02; most recent amendment 2024-08-08.
Trial Details
NCT Number NCT05841771
Lead Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions Hypomethylating Agent, Venetoclax, Myeloid Malignancy
Enrollment 78 participants
Start Date 2023-01-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-09